'On consolidated basis
Quarter ended September 2024 compared with Quarter ended September 2023.
Net sales (including other operating income) of Sun Pharmaceuticals Industries has increased 9.01% to Rs 13291.39 crore. Operating profit margin has jumped from 26.08% to 29.64%, leading to 23.89% rise in operating profit to Rs 3,938.96 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 13.79% to 12.50%. Purchase of finished goods cost fell from 8.34% to 6.67%. Employee cost decreased from 19.58% to 18.90%. Other expenses fell from 31.97% to 31.89%.
Other income rose 20.57% to Rs 354 crore. PBIDT rose 23.61% to Rs 4292.96 crore. Provision for interest rose 40.33% to Rs 69.17 crore. Loan funds rose to Rs 2,571.95 crore as of 30 September 2024 from Rs 1,928.23 crore as of 30 September 2023. Inventories decline...
Pleaselogin & subscribe to view the full report.
More Reports
|
|